James Carignan Has Been Appointed as Vice President, Quality Assurance and Regulatory Compliance for Bridge Pharmaceuticals in Beijing, China.

SAN FRANCISCO -- Bridge Pharmaceuticals announced today the appointment of James Carignan, B.S. RQAP-GLP as Vice President of Quality Assurance and Regulatory Compliance for its Beijing P.R.C. operations. Mr. Carignan comes to Bridge as a nationally recognized expert in Good Laboratory Practices (GLPs) with 25 years of experience in toxicology and analytical laboratories for multi-national corporations and CRO's. Prior to joining Bridge, Mr. Carignan was responsible for directing the quality assurance program at Novartis (formerly Chiron Corporation at Emeryville, CA). He is an expert in writing and implementing SOPs to support a GLP program, developing and conducting GLP training for all levels of senior staff, scientists, and general staff, and directing internal and external GLP site inspections. Mr. Carignan also previously held the position of Director of Quality Assurance and Regulatory Affairs at TherImmune Research where he was responsible for complete oversight of the QAU including maintaining the Master Schedule, Provantis data collection system validation processes, and preparation/submission of INDs.

Mr. Carignan is a member of several professional societies including the Society of Quality Assurance (SQA) and the Regulatory Affairs Professional Society (RAPS). He also has an HT certification (ASCP) and has been part of the SQA Regulatory Review Committee, including Chairman (1997-1998); and a long term member and Chairman of the SQA Educational Committee. He has been a Basic GLP Principle Trainer since 1999, and assisted the EPA in an OECD Submission in 1997. He has been an invited speaker at numerous meetings and conferences and has participated in continuing education programs throughout his career. He was invited to participate in the Drug Information Association's Red Apple II conference in 2006 and contributed to the initial RQAP-GLP exam.

Mr. Carignan was responsible for establishing numerous training programs within the SQA. He plans to utilize that experience, along with Bridge's facilities and resources, to establish and expand SQA's educational training and testing capabilities in China.

"People, process, passion is a company motto and Jim has them all," said Dr. Ada Kung, D.A.B.T, head of the Bridge Beijing Laboratory. "Jim is taking a leading role in quality assurance training and management in China at Bridge and, importantly for the industry, implementing the first ever US and EU level GLP program for drug safety testing in China. It has been a major accomplishment and we are absolutely thrilled to have him part of the team here in Beijing."

About Bridge Pharmaceuticals

Bridge is a preclinical CRO with state-of-the-art facilities in Gaithersburg, Maryland and Beijing, China, providing US GLP compliant pre-clinical contract research and development services. Services include general and specialized toxicology, developmental and reproductive toxicology (DART), safety pharmacology, gene tox, carcinogenicity testing and vaccine development in support of IND and NDA submissions. Studies are backed by in-house bioanalytical chemistry as well as histopathology and clinical pathology services that are all under the direction of US board certified pathologists and toxicologists. For more information, please visit www.bridgecro.com or contact the individuals below.

Copyright [c] 2007, Bridge Pharmaceuticals, Inc. All rights reserved.